AUG 03, 2015 11:05 PM PDT

Melanoma's Modus Operandi

WRITTEN BY: Ilene Schneider
Why does melanoma, which accounts for 2 percent of skin cancer cases, cause almost all skin cancer deaths? Why have melanoma rates in the US been rising rapidly over the last 30 years? What is melanoma's modus operandi?
Israeli researchers have unlocked puzzling trigger of melanoma.
A new study at Tel Aviv University (TAU), published in Molecular Cell and reported in Drug Discovery & Development, offers insight into the exact trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, showing the exact place in the process where "traveling" cancer turns deadly. Dr. Carmit Levy of the Department of Human Genetics and Biochemistry at TAU's Sackler School of Medicine led the study, which was conducted by a team of researchers from TAU, the Technion Institute of Technology, the Sheba Medical Center, the Institut Gustave Roussy and The Hebrew University of Jerusalem
(http://www.dddmag.com/news/2015/08/researcher-discovers-trigger-deadly-melanoma?et_cid=4710740&et_rid=45505806&location=top).

According to skincancer.org, melanoma is the most dangerous form of skin cancer. Cancerous growths develop when unrepaired DNA damage to skin cells triggers mutations (genetic defects) that cause the skin cells to multiply quickly and form malignant tumors that originate in the pigment-producing melanocytes in the basal layer of the epidermis. Melanomas, which look like moles, sometimes develop from moles. Most are black or brown, but they can also be flesh-colored, pink, red, purple, blue or white. Melanoma, which is caused mostly by intense, occasional UV exposure, especially in those who are genetically predisposed to the disease, kills an estimated 9,940 people in the US annually
(http://www.skincancer.org/skin-cancer-information/melanoma).

Melanoma that is caught in time can be removed and the patient's life saved, but if it invades the bloodstream, turning metastatic, the treatment is aggressive and not always successful. Dr. Levy wanted to know when and how the transformation into aggressive invasion took place. As he explained, "To understand melanoma, I had to obtain a deep understanding about the structure and function of normal skin. Melanoma is a cancer that originates in the epidermis, and in its aggressive form it will invade the dermis, a lower layer, where it eventually invades the bloodstream or lymph vessels, causing metastasis in other organs of the body. But before invading the dermis, melanoma cells surprisingly extend upward, then switch directions to invade. It occurred to me that there had to be a trigger in the microenvironment of the skin that made the melanoma cells 'invasive.' Using the evolutionary logic of the tumor, why spend the energy going up when you can just use your energy to go down and become malignant?"

The researchers collected samples of normal skin cells and melanoma cells from patients at hospitals around Israel, mixed normal and cancerous cells and performed gene analysis expression to study the traveling cancer's behavior. They discovered that, completely independently of any mutation acquisition, the microenvironment alone was the trigger for melanoma metastasis.

According to Dr. Levy "Normal skin cells are not supposed to 'travel.' We found that when melanoma is situated at the top layer, a trigger sends it down to the dermis and then further down to invade blood vessels. If we could stop it at the top layer, block it from invading the bloodstream, we could stop the progression of the cancer."

The researchers discovered that the direct contact of melanoma cells with the remote epidermal layer triggered an invasion by activating "Notch signaling," which activates a set of genes that stimulates changes in melanoma cells, making them invasive. They found that when a molecule expressed on a cell membrane - a spike on the surface of a cell, called a ligand - comes into contact with a melanoma cell, it transforms the cell into an invasive, deadly agent.

Dr. Levy concluded, "Melanoma is a cancer with a very long gestation period. If you can provide a simple kit with precise answers, you can catch it at the beginning stage and hopefully save lives."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
AUG 29, 2021
Cancer
Researchers Bioprint Deadly Brain Tumor with 3D Printer
AUG 29, 2021
Researchers Bioprint Deadly Brain Tumor with 3D Printer
Researchers have managed to print an entire active and viable glioblastoma tumor- the deadliest form of brain cancer- us ...
SEP 23, 2021
Immunology
Enhanced Hamster Cells as Super Drug Factories
SEP 23, 2021
Enhanced Hamster Cells as Super Drug Factories
Antibodies are highly specialized proteins produced by the immune system that stick on to foreign invaders in the body w ...
SEP 22, 2021
Cancer
Whole Genome Sequencing for Cancer Diagnostics
SEP 22, 2021
Whole Genome Sequencing for Cancer Diagnostics
The human genome consists of genetic material known as DNA.  We all have unique DNA sequences made up of four bases ...
DEC 06, 2021
Cancer
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
DEC 06, 2021
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer th ...
DEC 18, 2021
Cell & Molecular Biology
How the HTLV-1 Virus Can Turn Immune Cells Cancerous
DEC 18, 2021
How the HTLV-1 Virus Can Turn Immune Cells Cancerous
In some cases, viruses have been linked to cancer. For example, HPV, which is now preventable with a vaccine, can lead t ...
DEC 23, 2021
Cancer
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
DEC 23, 2021
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
It is estimated that nearly 84,000 people will be diagnosed with bladder cancer in the United States this year ...
Loading Comments...